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Acute encephalitisth mouse hepatitis virus, strain JHM (JHMV) develop a rapidly fatal acute
encephalitis. Previously, we showed that this disease is partially CD4 T cell-mediated since infection with a
recombinant JHMV (rJ) mutated in only a single immunodominant CD4 T cell epitope (epitope M133, rJ.
MY135Q) results in a nonlethal disease. Increased mortality correlated with a greater number of JHMV-speciﬁc
CD4 T cells in the brains of rJ compared to rJ.MY135Q-infected mice. Here, we extend these results to show that
the diminished number of virus-speciﬁc T cells correlates with a reduced cytokine/chemokine response in
the infected brain. We also show that regulatory CD4 T cells (Tregs) are critical for mild disease in rJ.MY135Q-
infected mice because their depletion results in increased mortality. Further, a relative paucity of Tregs
characterizes lethal infection because adoptive transfer of Tregs into rJ-infected mice increases survival from
0% to 50%. These results support the notion that clinical disease in coronavirus-induced acute encephalitis
results from a balance between factors critical for virus clearance, such as virus-speciﬁc effector T cells and
anti-inﬂammatory elements, such as Tregs. These ﬁndings also show that unlike chronic infections, in which
an excessive number of Tregs contributes to pathogen persistence, Tregs in the setting of acute encephalitis
may help to limit immunopathological disease without delaying virus clearance.
© 2008 Elsevier Inc. All rights reserved.IntroductionThe outcome of viral infections is dependent upon complex
interactions between the pathogen and host pro- and anti-
inﬂammatory immune responses. A dysregulated and overexuberant
innate immune response has been implicated in fatal H5N1 inﬂuenza
(de Jong et al., 2006) and may also be involved in the pathogenesis of
SARS (Severe Acute Respiratory Syndrome), caused by a novel
coronavirus (Perlman and Dandekar, 2005). Excessive T cell
responses have also been implicated in disease in mice infected
with lymphocytic choriomeningitis virus (LCMV), herpes simplex
virus or respiratory syncytial virus, with tissue damage occurring
during the process of virus clearance (Hussell et al., 2001; Oldstone,
2002; Suvas et al., 2004). To minimize excessive pro-inﬂammatory
responses, cells with anti-inﬂammatory activity, such as regulatory T
cells and Tr1 cells, which express IL-10 (Roncarolo et al., 2006), are
also induced during a normal immune response. An appropriate
anti-inﬂammatory response will prevent immunopathological dis-
ease without adversely affecting virus clearance. Regulatory T cells,
which suppress the pro-inﬂammatory response, encompass several
subsets including thymically derived CD4+CD25+ cells that expressrch was supported in part by
ple Sclerosis Society (RG 2864).
, BSB 3-712, University of Iowa,
man).
l rights reserved.the transcription factor Foxp3 (natural Tregs, abbreviated Tregs
herein) (Belkaid, 2007; Roncarolo and Battaglia, 2007). Many studies
have assessed the role of Tregs in autoimmunity, where a relative
deﬁciency of these cells occurs, and cancer, where they inhibit anti-
tumor T cell responses (Nomura and Sakaguchi, 2005; Sakaguchi,
2005; Sakaguchi et al., 2006). These cells have also been implicated
in chronic viral diseases. This was ﬁrst demonstrated in mice
infected with Friend's virus or herpes simplex virus and subse-
quently in humans infected with viruses such as hepatitis C virus
(HCV) and HIV (Belkaid, 2007; Belkaid and Rouse, 2005; Iwashiro et
al., 2001; MacDonald et al., 2002; Robertson and Hasenkrug, 2006;
Suvas et al., 2004). In infectious settings, Tregs can dampen the
immune response, thus minimizing tissue damage but at the cost of
inhibiting virus clearance (reviewed in Belkaid, 2007; Belkaid and
Rouse, 2005; Robertson and Hasenkrug, 2006).
Tregs might be predicted to have a lesser role in acute viral
diseases, since these infections are often characterized by uncon-
trolled virus replication and rapid disease progression. In murine
coronavirus-induced acute encephalitis, mice infected with the
neurovirulent JHM strain (JHMV) of mouse hepatitis virus (MHV)
develop a fatal disease with death occurring at 7–8 days p.i. (Stohlman
et al., 1998). Virus-speciﬁc T cells are ﬁrst detected in the brain at
6 days p.i., 24–48 h prior to the death of the animals. In C57BL/6 (B6)
mice, the majority of brain-derived CD8 T cells recognize two epitopes
in the surface (S) glycoprotein (S510 and S598), and 20–25% of CD4 T
cells respond to a single epitope, (M133, spanning residues 133–147 of
the transmembrane (M) protein) (Haring et al., 2001).
Table 1
Levels of cytokines and chemokines in the brains of rJ and rJ.MY135Q-infected mice
Virus IL-1βa IL-6a IFN-γa TNF-αa CCL2a CCL5a
Day 5
rJ 50.8±5.2 94.9±8.9⁎⁎ 36.1±8.5⁎ 738.3±266.8 2827.2±329.1⁎⁎ 417.9±12.5⁎⁎
rJ.MY135Q 37.4±2.8 46.7±16.2 13.6±3.2 390.3±66.3 598.0±204.9 171.1±49.8
Day 7
rJ 11.5±1.4 13.0±4.4 16.9±3.3 39.8±2.5 1019.4±293.1 449.9±16.5
rJ.MY135Q 12.8±1.0 5.0±0.6 13.4±3.9 37.5±1.6 476.6±189.1 311.4±112.6
a pg/ml.
⁎ pb0.05.
⁎⁎ pb0.02, when rJ and rJ.MY135Q-infected mice are compared.
359D. Anghelina et al. / Virology 385 (2009) 358–367While disease is generally attributed to the extensive neuronal
damage observed in these mice (Dubois-Dalcq et al., 1982; Kyuwa and
Stohlman, 1990), we recently showed that the JHMV-speciﬁc CD4 T cell
response contributed to a fatal outcome (Anghelina et al., 2006). InfectingFig. 1. Regulatory T cells in the brains of mice inoculated with rJ or rJ.MY135Q. (A) Cells were ha
CD4, CD25 and Foxp3. The number of CD4+CD25+ cells that express Foxp3 is shown (n=8 for e
brains of mice infectedwith rJ or rJ.MY135Q at 7 days p.i. (n=5 for each virus). (C) Frequency of
virus at each time point). (D, E) Cells were harvested from the brains of mice infected with rJ
M133, S358, S333-speciﬁc) by IFN-γ intracellular staining at the indicated times. Numbers
analyzed at each time point. (F) Cells were harvested from the brains of mice infected with rJ
T cells expressing Foxp3 is indicated. Representative histograms are shown. Four mice infec
were detected in infected mice at day 3 p.i.mice with a recombinant JHMV (rJ) in which M133 was mutated (rJ.
MY135Q) so that it was no longer recognized by CD4 T cells resulted in a
change in mortality from 100% to 0% without changes in the virus-
speciﬁc CD8 T cell response, in the Th2 CD4 T cell response or in thervested at 7 days p.i. from the brains of mice infected with rJ or rJ.MY135Q and stained for
ach virus). ⁎⁎pb0.02. (B) Numbers of CD4 Tcells that are CD25+Foxp3+ or CD25−Foxp3+ in
CD4 Tcells that are Foxp3+ in CLN of rJ and rJ.MY135Q-infectedmice (n=3–5mice for each
or rJ.MY135Q and analyzed for numbers of Tregs and virus-speciﬁc CD4 T cells (epitopes
of virus-speciﬁc CD4 T cells and Tregs are shown. Three to eight mice per virus were
or rJ.MY135Q at 3 days p.i. and stained for CD4, CD25 and Foxp3. Percentage of CD4+CD25+
ted with each virus were analyzed. Of note, very few CD4 T cells (approximately 2000)
360 D. Anghelina et al. / Virology 385 (2009) 358–367kinetics of virus clearance (Anghelina et al., 2006). Severe disease
correlated with a greater number of virus-speciﬁc Th1 CD4 T cells in the
brain. These results, showing that the virus-speciﬁc CD4 Tcell response is
partly pathogenic, raise the possibility that a more potent anti-Fig. 2. Functional and phenotypic characterization of Tregs harvested from infected mice. (
rJ or rJ.MY135Q were stained directly ex vivo for CD4, CD25, Foxp3 and GITR, CD103, CD69
ﬁgure. (B) CD4+CD25+ (Tregs) and CD4+CD25− (non-Tregs) T cells were sorted from the CL
CD4+CD25− and CD8+ cells were prepared from the lymph nodes of naive mice, labeled w
Tregs or non-Tregs and irradiated splenocytes at the indicated ratios (Treg or non-Treg
cytometry as described in Materials and methods.inﬂammatory response would minimize the collateral effects of the
anti-viral immune response, ideally without delaying virus clearance.
Here we substantiate the notion that the inﬂammatory response is
diminished in rJ.MY135Q-infected mice by showing that levels of pro-A) Mononuclear cells harvested at 7 days p.i. from the brains of B6 mice infected with
, CD62L or CD44. Cells harvested from a rJ.MY135Q-infected mouse are shown in the
N of rJ.MY135Q-infected B6 mice (7 days p.i.) as described in Materials and methods.
ith CFSE, stimulated with 1 μg/ml anti-CD3 and incubated for 72 h with the sorted
: CD8 or CD4+CD25−). Cells were analyzed for CFSE dilution (proliferation) by ﬂow
361D. Anghelina et al. / Virology 385 (2009) 358–367inﬂammatory cytokine/chemokines are lower in the brains of thesemice
compared to those infected with rJ. Further, since Tregs are believed to
contribute to the anti-inﬂammatory response,we reasoned that a relative
deﬁciency of these cells might contribute to rJ-mediated encephalitis.
Here we demonstrate that this is indeed the case and that Tregs have a
protective role in the context of a rapidly fatal acute infectious disease.
Results
Levels of proinﬂammatory cytokines and chemokines are greater in the rJ
relative to the rJ.MY135Q-infected CNS
rJ-infected mice develop fatal acute encephalitis, whereas mice
infected with rJ.MY135Q develop a nonlethal mild encephalitis and these
differences correlate with numbers of JHMV-speciﬁc CD4 T cells in the
brain (Anghelina et al., 2006). Since the host response to infection is
determined by relative contributions of pro and anti-inﬂammatory
factors, we reasoned that increased clinical disease in rJ-infected mice,
when compared to those infected with rJ.MY135Q, might result from not
only an increased number of virus-speciﬁc CD4 Th1 cells, but also higher
levels of pro-inﬂammatory cytokines and chemokines. To investigate this
possibility, we measured protein levels of several molecules known to be
upregulated in the brains of JHMV-infectedmice (IL-1β, IL-6, IFN-γ, TNFα,
CCL2, CCL5) (Bergmann et al., 2006) at days 5 and 7 p.i. (Table 1).
Signiﬁcantly higher levels of IL-6, CCL2, CCL5 and IFN-γ , but not IL-1β or
TNF-αwere measured in rJ compared to rJ.MY135Q-infected mice at day 5
p.i. In general, levels of cytokines were lower at day 7 when compared to
day 5, in agreementwith previous studies (Rempel et al., 2004), but levels
of IL-6, CCL2 and CCL5 remained increased in rJ compared to rJ.MY135Q-
infected brains. Elevated levels of pro-inﬂammatory cytokines, particu-
larly IL-6 and TNF-α, have been associated with decreased Treg function
(Korn et al., 2007) and autoimmunity is diminished in IL6−/−mice, in part
because Tregs are fully suppressive in the absence of this cytokine (Pasare
and Medzhitov, 2003). IL-6 was signiﬁcantly lower and disease was
milder in rJ.MY135Q compared to rJ-infected mice, prompting us to assess
levels and function of Tregs in infected mice.
Rates of accumulation and numbers of Tregs are different in rJ and rJ.
MY135Q-infected brains
To determine whether Tregs also contributed to the more modest
inﬂammatory milieu detected in rJ.MY135Q-infected mice, we measured
the numbers of CD4+CD25+Foxp3+ cells in the brains of infected mice at
day 7 p.i. by ﬂow cytometry, the time when most rJ-infected mice die
from acute encephalitis. As shown in Fig. 1A, a greater number of Tregs
were detected in the brains of rJ.MY135Q compared to rJ-infected mice.
Other studies have shown that CD4+CD25−Foxp3+ cells are as immuno-
suppressive as CD4+CD25+Foxp3+ cells (Kim and Rudensky, 2006). In
subsequent experiments, we showed that the majority of Foxp3+ cells inFig. 3. Identiﬁcation of epitope M133-speciﬁc Tregs in rJ-infected mice. (A) Cells were harve
CD4 Tcells by staining with speciﬁc and non-speciﬁc (human CLIP-speciﬁc)MHC class II tetram
Frequencies of M133-speciﬁc Tregs (CD4+Foxp3+) and M133-speciﬁc non-Tregs (CD4+Foxp3the brains of rJ and rJ.MY135Q-infected mice expressed CD25 (Fig. 1B).
Thus, total numbers of Foxp3+ cells in the brains of mice infected with rJ.
MY135Q were greater than in rJ-infected brains even when CD25−Foxp3+
cells were included in the analyses. These differences were conﬁned to
the brain because nearly identical percentages of Tregs were detected in
the draining (cervical) lymph nodes (CLN) of rJ and rJ.MY135Q-infected
mice (Fig. 1C), suggesting that Tregs attenuated the immune response at
the site of inﬂammation (brain) in rJ.MY135Q-infected mice.
We next determined the temporal relationship between the
numbers of Tregs (CD4+CD25+Foxp3+) and virus-speciﬁc effector
CD4 T cells in the brains of mice infected with rJ or rJ.MY135Q (Figs.
1D,E). Of note, we previously showed that, at each time point, similar
numbers of total CD4 T lymphocytes were detected in rJ and rJ.MY135Q-
infected brains (Anghelina et al., 2006). We used IFN-γ expression as a
marker for effector Th1 CD4 T cells since virtually no Th2 CD4 T cells
are present in infected brains as assayed by expression of IL-5
(Anghelina et al., 2006). In addition to epitope M133, at least two
additional CD4 T cell epitopes, encompassing residues 333–347 and
358–372, are recognized in JHMV-infected B6 mice (Xue and Perlman,
1997). Wewere consistently able to detect CD4+CD25+Foxp3+ T cells in
the brain as early as day 3 after infection with either virus (Fig. 1F,
equivalent to approximately 50–100 Tregs/brain) but could not
reliably identify JHMV-speciﬁc CD4 T cells using an intracellular IFN-
γ assay until day 6 p.i. In the rJ-infected brain, the numbers of Tregs
decreased and virus-speciﬁc effector CD4 T cells greatly increased
between 6 and 7 days p.i. These changes coincided with the time
when mice become moribund. In contrast, numbers of Tregs
predominated in the rJ.MY135Q-infected brain at all time points up to
14 days p.i.; these mice developed minimal clinical disease with no
mortality. Of note, it is striking that the numbers of Tregs in the rJ-
infected brain was much higher than in the brains of mice infected
with rJ.MY135Q at day 6 p.i. (Figs. 1D,E). However, these cells were
unable to protect mice from lethal disease and their number
decreased considerably over the next 24 h. While these results may
reﬂect the greater number of virus-speciﬁc CD4 T cells present in the
rJ-infected brain, it is also possible that the elevated levels of IL-6
present in the brains of rJ-infected mice resulted in a loss of
functionality, as previously described in mice with EAE (acute
autoimmune encephalomyelitis) (Korn et al., 2007).
To verify that these CD4+CD25+Foxp3+ cells were phenotypically
Tregs, we stained brain-derived cells for GITR, CD103, CD62L, CD69
and CD44 (Fig. 2A). No differences were observed in marker
expression when Tregs from rJ and rJ.MY135Q-infected brains were
compared. Most importantly, both CD103 (αɛ integrin), associated
with targeting Tregs to sites of inﬂammation, and GITR (glucocorti-
coid-induced tumor necrosis factor receptor family-related gene)
were expressed at higher levels on CD4+CD25+Foxp3+ cells than on
either CD4+CD25+Foxp3− or CD4+CD25−Foxp3− cells. Most Tregs were
CD62L−. Thus, these cells had the phenotype of “effector/memory”sted from the brains of infected Foxp3-GFP mice and assayed for epitope M133-speciﬁc
ers and anti-CD4 antibody. Cells shown in the ﬁgurewere gated for CD4 expression. (B)
−) within total CD4 T cells in the brain are shown. Ten mice were analyzed.
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a site of inﬂammation (Huehn and Hamann, 2005).
To show that these CD4+CD25+Foxp3+ cells were functionally
Tregs, we analyzed their suppressive capability in in vitro proliferation
assays. For these experiments, CD4+CD25+ and CD4+CD25− Tcells were
harvested from the CLN of rJ.MY135Q-infected mice at day 7 p.i. and
incubated with CFSE-labeled CD4+CD25− or CD8 T cells, obtained from
naive mice, in the presence of anti-CD3 antibody and irradiated
splenocytes. We used Tregs from CLN in these assays because only
small numbers of Tregs could be harvested from the rJ.MY135Q-infected
brain (maximum of about 10,000 Tregs/brain, assuming complete
recovery (Fig. 1E)) and brain-derived lymphocytes do not generally
survive in in vitro cultures (Irani et al., 1997). These CD4+CD25+ cells
but not CD4+CD25− T cells potently suppressed CD4 and CD8 T cell
proliferation (Fig. 2B). Thus, Tregs were present in higher numbers
than JHMV-speciﬁc effector T cells in the brains of rJ.MY135Q-infected
mice at all time points and were phenotypically and, by extrapolation
from these studies of CLN-derived Tregs, functionally identical toTregs
described in other settings (Nomura and Sakaguchi, 2005; Sakaguchi,
2005; Sakaguchi et al., 2006).
Virus-speciﬁcity of Tregs in the brains of infected mice
In some instances, Tregs recognizing an antigen present at the site
of inﬂammation are more potently immunosuppressive than natural
Tregs (Tang and Bluestone, 2006; Tarbell et al., 2007). Therefore, to
determine whether Tregs in the brain are virus-speciﬁc, we used MHC
class II/peptide M133 tetramers to detect M133-speciﬁc Tregs in rJ-
infected mice. Because intracellular staining for Foxp3 requires
permeabilization, which diminishes tetramer binding, we infected
Foxp3gfp knock-in mice (Fontenot et al., 2005), in which Tregs areFig. 4. Increasedmortality andweight loss in rJ.MY135Q-infectedmice after Treg depletion. (A)
infection with rJ.MY135Q. Percentage of Foxp3+CD25+ of total CD4 T cells in the brain at day 5
days after treatment with anti-CD25 antibody (n=10) or rat IgG (n=15) and monitored for su
Mortality (pb0.05) and weight loss (pb0.05 at days 8–13) were signiﬁcantly increased in an
mAb PC61 or rat IgG (n=5 for each antibody).identiﬁed by GFP expression without a requirement for permeabiliza-
tion. We found that 8.8±0.9% (n=10) of Foxp3− CD4 T cells in the brain
were M133-speciﬁc (Fig. 3) by tetramer staining. Only 1.2%±0.3%
(n=10) of Foxp3+(GFP+) CD4 T cells bound tetramer M133. Although
this likely represents a minimal estimate of the number of virus-
speciﬁc Tregs in the brain, we did not further investigate their
protective role because they were present in such low numbers.
Morbidity and mortality were increased in rJ.MY135Q-infected mice after
Treg depletion
While these results demonstrate the presence of Tregs in the infected
CNS, theydonot showwhether these cells are immunosuppressive invivo.
If Tregs have a signiﬁcant role in protection, they should be critical for
limiting disease in rJ.MY135Q-infected mice. Consequently, their depletion
should result in enhanced disease. Therefore, we depleted Tregs by
treatment with anti-CD25 mAb (mAb PC61) three days prior to infection
with rJ.MY135Q; this treatment resulted in an approximate 90% decrease in
Tregs in the infected brain at 5 days p.i. (Fig. 4A). Anti-CD25-treated mice
developed signiﬁcant weight loss and a mortality of 50% whereas control
mice, treated with rat IgG, developed only mild disease and uniformly
survived the infection (Figs. 4B,D). By decreasing the anti-inﬂammatory
environment, Treg depletion might facilitate virus clearance. However,
depletion of these cells did not change virus clearance in rJ.MY135Q-
infected mice, as similar levels of infectious virus were measured at day 5
p.i. in control and Treg-depleted mice (Fig. 4C). Of note, we measured
levels of a single representative cytokine, IL-6, at day 5 p.i. to determine
whether mAb PC61 treatment resulted in increased cytokine/chemokine
levels. Day 5 p.i. was chosen because levels diminish greatly by day 7 p.i.
(Fig. 1). However, we saw no statistically signiﬁcant differences in IL-6
levels when IgG and anti-CD25-treated mice were compared. This lack ofMicewere treated with 0.5 mg anti-CD25 antibody (mAb PC61) or rat IgG 3 days prior to
p.i. (8 days post treatment) is shown. (B, D) B6 mice were infected with rJ.MY135Q three
rvival (B) and weight loss (D). Results from three independent experiments are shown.
ti-CD25 mAb-treated mice. (C) Viral titers in the brain at day 5 p.i after treatment with
363D. Anghelina et al. / Virology 385 (2009) 358–367difference may have occurred because only 50% of mice died after PC61
treatment and it was not possible to identify these mice at day 5 p.i.
Enhanced survival in rJ-infected recipients of transferred Tregs
Conversely, a relative deﬁciency of Tregs might contribute to
the increased mortality observed in rJ-infected mice. To assess thisFig. 5. Increased survival after adoptive transfer of Tregs into rJ-infected mice. (A) CD4+CD25
98% pure as assessed by ﬂow cytometry. (B) 3.7×105 CD4+CD25+ T cells were adoptively tran
CD4+CD25− cells or PBS. Mice were monitored for survival (B) and weight loss (C). Three ind
cells survived at a higher frequency than those receiving CD4+CD25− cells or PBS (pb0.05). (D
or PBS at day 7 p.i. Fourmice were analyzed in each group. (E) Tregs were puriﬁed from the sp
rJ. Mice were sacriﬁced at day 5 or 7 p.i. and Tregs from brains, spleens, CLN and periphera
analyzed at each day p.i. in two independent experiments. (F) Brains and CLN were harvested
Foxp3+ CD4 T cells were determined by ﬂow cytometry. (G) IL-10−/− (n=5) or B6 Tregs (n=
independent experiments were performed. Mice were monitored for survival. A.T.—adoptivpossibility, we adoptively transferred CD4+CD25+ Tregs from naive
B6 spleens into infected animals. The purity of the transferred
cells was consistently 95–98% (Fig. 5A). These cells were functional
in in vitro proliferation assays, performed as described in Fig. 2A
(data not shown). In preliminary experiments, we observed
optimal protection when cells were transferred one day p.i. so
transfers were performed at this time in subsequent experiments.+ T cells isolated from naive B6 spleens as described in Materials and methods were 95–
sferred into mice at day 1 after infection with rJ. As a control, rJ-infected mice received
ependent experiments were performed, n=10 mice/group. Mice receiving CD4+CD25+ T
) Virus titers were the same in rJ-infected recipients of CD4+CD25+ or CD4+CD25− T cells
leens of naive Thy1.1 mice and transferred intoThy1.2 B6mice 1 day after infectionwith
l (PLN) lymph nodes were analyzed for Thy1.1/1.2 expression. A total of ﬁve mice were
at days 5 and 7 p.i. from rJ-infectedmice that received CD4+CD25+ or CD4+CD25− T cells.
4) or CD4+ CD25−IL-10−/− T cells (n=3) were transferred into B6 mice at day 1 p.i. Two
e transfer.
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mice from 0% to 50%, but had no signiﬁcant effect on weight loss
(Figs. 5B,C). Transfer of the same number of CD4+CD25− T cells did
not prolong survival and had no effect on weight loss (Figs. 5B,C).
In other experiments, we observed that transfer of as few as 105
Tregs to rJ-infected mice also resulted in protection (50% survival)
but recovery was prolonged. In some instances, such as in mice
with EAE (Izcue et al., 2006; Zhang et al., 2004), Treg mediate
immunosuppression via expression of IL-10. However, adoptively
transferred IL-10−/− Tregs were as effective in protecting mice from
death in rJ-infected mice as were B6 Tregs (Fig. 5G).
Although these results showed that transferred Tregs prolonged
survival, we were unable to demonstrate any differences in virus titers
or in the virus-speciﬁc T cell immune response when we compared
recipients of Tregs and CD4+CD25− T cells. Initially, we measured virus
titers in the brain at day 7 p.i. in mice that received Tregs, CD4+CD25− T
cells or no transferred cells, to determine if Tregs delayed virus
clearance. However, as shown in Fig. 5D, adoptive transfer of Tregs did
not change virus titers at day 7 p.i. Mice that did not receive Tregs died
by days 7–8 p.i. precluding measurement of titers at later times. Of
note, infectious virus was completely cleared by day 18 p.i. from
surviving Treg-treated mice.
Next, to begin to assess whether the transferred Tregs suppressed
the anti-virus T cell response, we determined their site of localization.
Preferential accumulation in the CLN would suggest an effect during
priming or accumulation in the brain would be consistent with a role
in modulating T cell function during the effector stage. To distinguish
transferred Tregs from endogenous cells, we transferred Thy1.1 Tregs
into B6 (Thy1.2) mice. Unexpectedly, given the clinical effect of the
transferred Tregs, only a low percentage of Tregs at any site examined
(brain, CLN, peripheral lymph nodes, spleen) were donor in origin (Fig.
5E). This percentage was not increased in the brain or CLN compared
to the spleen or more distant lymph nodes. In other studies,
transferred Tregs, even if present in low numbers, were able to induce
the proliferation or retention of endogenous Tregs (Tarbell et al.,
2007). However, we detected no difference in the percentage of Tregs
in the brain or CLN of mice that received Tregs when compared to
those that received CD4+CD25− T cells (Fig. 5F).
As these initial assays did not provide insight into themode of action
of the transferred Tregs, we next assessed whether these cells modiﬁed
the virus-speciﬁc T cell response in the infected brain. However we
detected only marginally lower numbers of S510-speciﬁc CD8 and
M133-speciﬁc CD4 T cells in recipients of CD4+CD25+ cells (Table 2); the
difference in percentage of S510-speciﬁc CD8 T cells in Treg recipients
(7.7±1.4) compared to those receiving CD4+CD25− T cells (12.2±1.6)
nearly reached statistical signiﬁcance (p=0.06) while there were no
differences in percentages of M133-speciﬁc CD4 T cells. Only very low
frequencies of JHMV-speciﬁc CD8 and CD4 T cells are detectable in the
CLN (Haring et al., 2001) and we detected no differences in these
numbers when mice that received Tregs or CD4+CD25− cells were
compared (data not shown).
Discussion
This study supports the notion that the outcome in coronavirus-
induced encephalitis results from a balance between pro-inﬂammatory
modalities required for virus clearance and anti-inﬂammatory factors,Table 2
Ag speciﬁcity of CD4 and CD8 T cells in rJ-infected recipients of transferred cells
Donor cells No. analyzed CD8
% CD8 % S510/CD8
(% irrelevant peptide)
N
CD4+CD25+ 7 12.7±2.7 7.7±1.4(2.4±0.3) 1
CD4+CD25− 9 11.1±1.5 12.2±1.6(3.6±0.5) 1such as Tregs, necessary to prevent an excessive, deleterious host
immune response. This response does not necessitate a numerical
superiority of Tregs to virus-speciﬁc effector T cells, but rather the
presence of sufﬁcient numbers of both cell types and of a balanced
cytokine environment, which cooperate to clear virus and minimize
tissue destruction. The importance of this balance was illustrated when
rJ and rJ.MY135Q-infected mice were compared. Both rJ and rJ.MY135Q
grew equally well in tissue culture cells and to similar titers in B6 mice,
with equivalent kinetics of clearance (Anghelina et al., 2006). However,
differences in thebalance betweenvirus-speciﬁc effector CD4 Tcells and
Tregs correlated with dramatic differences in survival and depletion or
transfer of Tregs also inﬂuenced the outcome. Greater numbers of virus-
speciﬁc effector CD4 T cells (Fig. 2), associated with increased levels of
several pro-inﬂammatorymediators (Fig.1), were detected in the brains
of rJ compared to rJ.MY135Q-infected mice (Anghelina et al., 2006) and
likely contributed tomore severe disease and a uniformly fatal outcome.
IL-6 may be especially important in contributing to a fatal outcome
because this cytokine, in conjunction with TNF, is able to inhibit Treg
function even when Tregs are present in substantial numbers in the
inﬂamed brain (Korn et al., 2007). In the presence of fewer virus-speciﬁc
CD4Tcells, as occurred in rJ.MY135Q-mice, theeffectof anti-inﬂammatory
factors such as Tregs was dominant. Thus, a nearly ideal balance is
present in rJ.MY135Q-infectedmice, inwhich clearance of a virulent virus
occurs with minimal clinical disease.
Whether Tregs function primarily during T cell priming or in the
infected brain during the effector stage of the inﬂammatory process
requires further clariﬁcation. Differences in numbers of Tregs in the
brains but not the CLN of rJ and rJ.MY135Q-infected mice suggest that
these cells function during the effector stage in ameliorating disease.
At the peak of the infection, there were approximately 10,000 and
20,000 Tregs in the rJ.MY135Q and rJ-infected brain, respectively. While
this represents only about 5–15% of all CD4 T cells, these percentages
are consistent with those observed in other inﬂammatory settings in
the brain (Korn et al., 2007; O'Connor et al., 2007). The mechanism of
Treg-mediated immunosuppression in the rJ.MY135Q-infected brain is
not known, but may involve production of molecules such as TGF-β or
IL-35 as occurs in other experimental settings (Vignali et al., 2008); our
data suggest that Tregs do not function via IL-10 expression (Fig. 5G).
We could not determine whether adoptively transferred Tregs
functioned in the brain or CLN. While these transferred cells increased
survival, they did not delay virus clearance or signiﬁcantly modify the
anti-virus T cell response, as measured by IFN-γ expression. Several
explanations are possible for this inability to demonstrate a mechan-
ism of action of the transferred Tregs. First, since mice that do not
receive transferred Tregs uniformly die by days 7–8 p.i., all assays
must be performed at this time. However, at this time p.i., mice that
will survive after Treg transfer cannot be distinguished from those
that will not, thus potentially obscuring any effects of the transferred
Tregs. Second, as shown in Fig. 4, only 50% of Treg recipients survive
and there are no signiﬁcant differences in weight loss between
recipients of Tregs as opposed to those mice that receive CD4+CD25−
cells. Thus the Tregs play an important role in enhancing survival, but
all mice, whether they survive or not, have severe disease. Other
factors with anti-inﬂammatory activity, such as IL-10, may also
function sub-optimally in rJ-infected mice and enhancing their
function, in conjunction with the transfer of Tregs, may contribute
to an improved clinical course and more obvious changes in theCD4
o. S510 % CD4 % M133/CD4
(% no peptide)
No. M133
.4×104±0.5×104 1.7±0.2 19.1±2.4(4.4±0.7) 4.2×103±0.8×103
.8×104±0.4×104 1.9±0.2 18.7±1.3(1.9±0.2) 5.5×103±1.1×103
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mice with an attenuated variant of JHMV (Lin et al., 1998) or rJ.MY135Q
(data not shown) resulted in increased mortality and weight loss,
showing that IL-10 is required for optimal disease outcome. Our
results show, however, that Treg expression of IL-10 is not required for
the protective effects of transferred cells in rJ-infected mice (Fig. 5G),
suggesting that IL-10 must be produced by another type of cell in
infected mice. In other infections, macrophages, dendritic cells and
CD4+Foxp3− T cells have all been shown to express IL-10 (reviewed in
Couper et al., 2008). Third, Tregs function by cell-to-cell contact with
either dendritic cells at sites of priming or with effector T cells or other
cells in sites of inﬂammation (Tadokoro et al., 2006; Tang et al., 2006;
Vignali et al., 2008). It is possible that the transferred Tregs function to
subtly change the immune response in a localized manner without
globally affecting total numbers of virus-speciﬁc T cells.
The importance of virus-speciﬁcity of Tregs in JHMV-infected mice
is not yet known. Antigen-speciﬁc Tregs more effectively suppress the
response of T effector cells to cognate antigen than non-antigen-
speciﬁc Tregs (Tang and Bluestone, 2006; Tarbell et al., 2007), but our
results show that very few virus-speciﬁc Tregs are present in the
infected brain (Fig. 3). It is also likely that the effects mediated by
transferred natural Tregs in rJ-infected mice do not require virus-
speciﬁcity, since transfer of a relatively low number (3.7×105 cells, Fig.
5) reduced mortality. Only a few JHMV-speciﬁc naive Tregs should be
present in this number of cells, suggesting that if antigen speciﬁcity is
required for Treg function, virus-speciﬁc Tregs would need to expand
rapidly in order to dampen the pro-inﬂammatory immune response.
Treg numbers could also be increased by peripheral conversion of
CD25−CD4+ T cells to Tregs but the extent to which peripheral
conversion occurs within the brain is controversial. While Liu et al.
reported that neurons are able to induce conversion of effector CD4 T
cells to CD25+TGFβ1+CTL4+Foxp3+ cells in the context of EAE (Liu et al.,
2006), others have found no evidence for such conversion in the same
setting (Korn et al., 2007; O'Connor et al., 2007). It will be critical in
future studies to determine whether JHMV-speciﬁc Tregs are derived
from virus-speciﬁc effector CD4 T cells.
Our study is one of only a few that address the role of Tregs in acute
infectious disease (Luhn et al., 2007; Lund et al., 2008). Similar to our
results, a relative deﬁciency of these cells is present in patients with
severe acute dengue infection, when compared to those with mild
disease (Luhn et al., 2007). Our data are concordant with studies of
SIV-infected African green monkeys (AGM) and macaques. In infected
AGMs, Tregs are detected early after infection and dampen the initial
pro-inﬂammatory immune response. Furthermore, AGMs do not
develop the chronic T cell activation that is characteristic of the
progression to AIDS (Kornfeld et al., 2005). In macaques, which
develop AIDS, Tregs appear later and may actually inhibit an effective
anti-viral CD8 T cell response (Estes et al., 2006). Collectively, these
results suggest that optimization of Treg numbers and function at very
early times during the infectious process will diminish the likelihood
of an excessive immune response; our results show that this effect
may be sufﬁciently profound to prevent death in an otherwise lethal
disease.
Materials and methods
Mice
Speciﬁc pathogen-free 5–6 week old B6mice were purchased from
the National Cancer Institute, Bethesda, MD. IL-10−/− and Foxp3-GFP
mice were kindly provided by Drs. D. Elliot (University of Iowa) and A.
Rudensky (University of Washington), respectively. Mice were
inoculated intranasally (i.n.) with 4–8×104 plaque forming units
(PFU) of recombinant JHMV in 12 μL of DMEM andwere examined and
weighed daily. In all experiments, surviving mice were euthanized
18 days post infection (p.i.). Virus was harvested from the infectedbrain and titered by plaque assay on HeLa cells expressing the cellular
receptor for mouse hepatitis virus (HeLa-MHVR) (Perlman et al.,1987).
All animal studies were approved by the University of Iowa Animal
Care and Use Committee.
Viruses and cells
Recombinant JHMV was grown in mouse 17Cl-1 cells (a BALB/c-
derived ﬁbroblast cell line) and titered on HeLa-MHVR cells as
described previously (Perlman et al., 1987).
Multiplex assays
Brain homogenateswere prepared in 1.5ml cell lysis buffer (Bio-Rad,
Hercules, CA) containing protease inhibitors. Total protein concentration
was determined by Bradford assay. All tissue samples were diluted with
cell lysis buffer to a ﬁnal protein concentration of 500 μg/ml, irradiated
and aliquoted. Concentrations of IL-6, IL-1β, IFN-γ, TNF-α, RANTES
(CCL5),MCP-1 (CCL2)were determinedusing a Bio-Plex cytometric bead
array, as described (Hulse et al., 2004).
Antibodies and surface and intracellular staining
All antibodies were purchased from BD-Pharmingen (San Diego,
CA) unless indicated below. Lymphocytes were prepared from brains
as described previously (Anghelina et al., 2006). Brieﬂy, brains were
harvested from mice after PBS perfusion and were mechanically
homogenized using frosted glass slides. Cells were suspended in 30%
Percoll (Pharmacia, Piscataway, NJ) and centrifuged at 800 ×g at 4 °C for
30 min. Percoll and lipid layers were aspirated and the cell pellet was
resuspended and counted. The number of lymphocytes harvested from
each infected brain ranged from1–3×106. For detection of intracellular
cytokines, CD8 T cells were stimulated with peptide S510 (spanning
residues 510–518 of the S glycoprotein, 1.2 μM) or irrelevant peptide
(Ova 257–264). CD4 Tcells were stimulatedwith peptides correspond-
ing to epitopesM133, S358or S333used atﬁnal concentrations of 5 μM,
respectively. Intracellular expression of IFN-γ was detected as
previously described (Anghelina et al., 2006).
To detect Tregs, cells harvested from brains, spleens or lymph
nodes were stained for the transcription factor Foxp3 as per the
manufacturer. Brieﬂy, cells were stained with anti-CD4-FITC or -PerCP
(clone GK1.5) and anti-CD25-PE-Cy7 (clone PC61) mAbs. After
permeabilization and ﬁxation, cells were stained with either anti-
Foxp3-PE or FITC (clone FJK-16s) or isotype control Rat IgG2a-PE or
FITC (clone eBR2a)mAb, both purchased from eBiosciences (SanDiego,
CA). For phenotypic analysis of Tregs, cells were surface stained with
the following mAbs: anti-GITR-FITC (clone DTA-1), anti-CD103-PE
(clone 2E7), anti-CD44-PE (clone IM7), anti-CD69-PE (clone H1.2F3),
anti-CD62L-FITC (clone MEL-14) or anti-CD25-PE (clone 7D4). After
staining, washing and ﬁxation, cells were analyzed using a FACScan or
LSR Flow Cytometer (BD Biosciences, Mountain View, CA).
In some experiments, epitope M133-speciﬁc cells were detected
using MHC class II/peptide tetramers, obtained from the N.I.H.
Tetramer Facility, Atlanta, GA. Cells were stained with 8 μg/ml
tetramer for 2–3 h at 37 °C.
Puriﬁcation of CD4+CD25+ and CD4+CD25− T cells
CD4+CD25+ Tregs were puriﬁed using an autoMACS Separator and
a CD4+CD25+ Regulatory T Cell Isolation Kit (Miltenyi Biotec, Auburn,
CA) according to the manufacturer's protocol. Brieﬂy, lymphocytes
from spleens or lymph nodes were enriched for CD4 T cells by
depletion with a cocktail of lineage-speciﬁc biotin-conjugated
antibodies against CD8 (Ly-2), CD11b (Mac-1), CD45R (B220),
CD49b (DX5), Ter-119 and anti-biotin microbeads, followed by
positive selection with anti-CD25-PE mAb and anti-PE microbeads.
366 D. Anghelina et al. / Virology 385 (2009) 358–367The CD4+CD25− T cell population was subsequently depleted of
residual CD4+CD25+ cells using anti-CD25-PE mAb and anti-PE
microbeads. Cells were examined for purity by ﬂow cytometry and
were routinely found to be 96–98% pure.
In vitro CD4 and CD8 T cell proliferation assays
CD4+CD25− and CD8 T cells were puriﬁed from naive mouse lymph
nodes, labeled with freshly prepared CFSE (2 μM, Molecular Probes,
Carlsbad, CA) for 10min at 37 °C, washed 3 timeswith RP10media and
cultured in 96-well U-bottom plates (5×104 cells/well) in the presence
of 1 μg/ml anti-CD3 (clone 145-2C11; eBioscience) and 2×105
irradiated splenocytes (2500 Gy). Bead-puriﬁed CD4+CD25+ or CD4+
CD25− Tcells from naive or rJ.MY135Q-infected B6 cervical lymph nodes
(CLN) were added at ratios of 0.3:1, 1:1 and 3:1 in triplicate. Plates
were incubated at 37 °C for 72 h. Cells were harvested and analyzed
on a FACScan Flow Cytometer. Data were processed using FlowJo
software version 6.3.4 (Tree Star, Ashland, OR).
Adoptive transfer of CD4+CD25+ T cells
CD4+CD25+ T cells (1 or 3.75×105 cells in 0.5 ml PBS/mouse) were
puriﬁed from naive spleens and adoptively transferred by intravenous
inoculation into 5–6 week old B6 mice one day after infection with rJ.
Control rJ-infected mice received the same numbers of CD4+CD25− T
cells or PBS. Mice were monitored for mortality and weight loss. T cell
responses and virus titers were analyzed at 5 and 7 days p.i.
In vivo depletions
To deplete CD25+ cells, a single intraperitoneal injection of 0.5 mg
of rat mAb PC61 (American Type Culture Collection, Manassas, VA,
prepared by the University of Iowa hybridoma facility) or control rat
IgG (Jackson Immunoresearch, West Grove, PA) was administered
three days prior to infection with rJ.MY135Q.
Statistics
Two-tailed unpaired Student's t tests were used to analyze
differences in mean values between groups. All results are expressed
as means±standard errors of the means (SEM). p values of b0.05 were
considered statistically signiﬁcant.
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